We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Citius Pharmaceuticals reported the U.S. Food and Drug Administration (FDA) responded to the Company's proposal to refine the endpoints in the current Phase 3 pivotal trial for Mino-Lok.